In re: Flonase Antitrust Litigation
District Court: Eastern District of Pennsylvania Status: Pending
On December 22, 2017, the U.S. Court of Appeals for the Third Circuit ruled that an antitrust suit filed by Louisiana’s Attorney General against GlaxoSmithKline …
Mohr-Lercara v. Oxford Health Ins., Inc.
District Court: Southern District of New York Status: Pending
A proposed class action was filed in New York federal court accusing Oxford Health Insurance of overcharging patients for prescription drugs. The complaint alleges that …
In Re UnitedHealth Group PBM Litigation
District Court: District of Minnesota Status: Decided
Plan members brought suit against UnitedHealth Group, Inc. under ERISA and RICO for Defendants’ conduct in administrating pharmacy benefits that allegedly caused Plaintiffs to overpay …
Negron v. Cigna and OptumRx
District Court: District of Connecticut Status: Pending
Cigna faces a class-action lawsuit alleging the insurance giant overcharged its members by more than 10 times the amount the insurer paid for certain prescription …
Federal Trade Commission v. Actavis, Inc.
District Court: Northern District of Georgia Status: Decided
The Supreme Court ruled in favor of the FTC, holding that a brand name manufacturer’s payment to a generic competitor to settle patent infringement claims …
Federal Trade Commission v. Allergan and Watson Laboratories, Inc. et al.
District Court: Northern District of California Status: Decided
On January 23, 2017, the FTC refiled a complaint against Watson Laboratories and its former parent company, Allergan, for entering a pay-for-delay settlement with EndoPharmaceuticals to block a generic version of …
Walgreen Co. et al v. Allergan, Inc
District Court: Eastern District of New York Status: Pending
Four drug retailers, including Walgreens and Albertsons, filed an antitrust suit alleging that Allergan devised and carried out a multifaceted and anticompetitive scheme to maintain …
Association for Accessible Medicines v. Frosh
District Court: District of Maryland Status: Decided
In a significant victory for the pharmaceutical industry, the 4th U.S. Circuit Court of Appeals found Maryland’s landmark 2017 law (HB 631), which punishes generic …
PhRMA v. David
District Court: Eastern District of California Status: Decided
PhRMA challenged California’s drug price transparency law SB 17 alleging that the law is unconstitutional because it violates the Commerce Clause, the First Amendment, and …
Pharmaceutical Care Management Association (PCMA) v. Rutledge
District Court: Eastern District of Arkansas Status: Decided
Act 900 (SB 688), enacted in 2015, required disclosure of generic drug pricing and sets a floor on prices that PBMs can pay to pharmacies …
PhRMA and BIO v. Sandoval
District Court: District of Nevada Status: Decided
In September 2017, just three months after Nevada passed its insulin transparency law (SB 539) in June 2017 to increase transparency over the price of …
In re Express Scripts/Anthem ERISA Litigation
District Court: Southern District of New York Status: Pending
The district court dismissed a proposed class action against Anthem Inc. and Express Scripts Inc. over drug pricing methods, holding that the companies can’t be …
Alcon Labs., Inc. v. Cottrell
District Court: District of New Jersey Status: Decided
Consumers brought putative class action against manufacturers and distributors of prescription eye medication, alleging they packaged medication in such a way as to force consumers …
Drogueria Betances LLC v. Novartis Pharmaceuticals Corp.
District Court: Southern District of New York Status: Pending
Novartis Pharmaceuticals Corp. allegedly agreed with Par Pharmaceuticals Inc. to squelch generic competition to Novartis’s hypertension drug Exforge, resulting in buyers paying millions more than …
Federal Trade Commission v. AbbVie Inc. et al.
District Court: Eastern District of Pennsylvania Status: Decided
FTC alleged AbbVie sued generic companies for patent infringement over their proposed generic version of the testosterone gel, AndroGel, without justifiable grounds but merely to …
In the Matter of Impax Laboratories Inc.
District Court: Federal Trade Commission Status: Pending
The Federal Trade Commission sued generic drugmaker Impax Laboratories Inc. for allegedly accepting more than $100 million to delay its release of a generic version …